Cysteine-Rich Angiogenic Inducer 61 Serves as a Potential Serum Biomarker for the Remission of Adult-Onset Still's Disease

Frontiers in Medicine

article

Yutong Su¹  Xiaobing Cheng¹  Hui Shi¹  Jialin Teng¹  Chengde Yang¹  Yue Sun¹  Zhihong Wang¹  Junna Ye¹  Tienan Feng²  Fan Wang¹  Huihui Chi¹  Zhuochao Zhou¹  Qiongyi Hu¹  Honglei Liu¹ 

[1] Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine;Clinical Research Institute, Shanghai Jiao Tong University School of Medicine

关键词: adult-onset Still's disease;    cysteine-rich angiogenic inducer 61;    disease activity;    biomarker;    disease remission;   

DOI  :  10.3389/fmed.2019.00266

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Objective: Adult-onset Still's disease (AOSD) is a rare, polygenic, systemic autoinflammatory disease. The aim of this study is to evaluate the serum levels of cysteine-rich angiogenic inducer 61 (Cyr61), a secreted, extracellular protein in AOSD patients. Methods: A total of 60 AOSD patients (39 of active phase and 21 of inactive phase), 16 rheumatoid arthritis patients as a disease control, and 34 sex- and age-matched healthy control subjects (HC) were enrolled in the study. The data of the clinical manifestations and laboratory examinations were collected. The serum levels of Cyr61, interleukin (IL)-17, and IL-37 were detected by ELISA assay, and the serum levels of IL-10, IL-1β, IL-6, IL-18, and tumor necrosis factor (TNF)-α were examined by electrochemiluminescence assay. Results: The serum levels of Cyr61 were significantly increased in inactive AOSD than those in active patients and HCs, and the levels of Cyr61 were dramatically increased after treatment. The levels of Cyr61 were inversely correlated with systemic score, the counts of leukocyte and neutrophil, and the levels of inflammatory cytokines (IL-1β, IL-6, and IL-17). Moreover, the levels of Cyr61 were higher in patients without the clinical symptoms of fever, skin rash, sore throat, arthralgia, and lymphadenopathy compared with those in patients with these symptoms. Conclusion: The serum levels of Cyr61 were inversely correlated with disease activity in AOSD patients; thus, we proposed that Cyr61 was a biomarker for the remission of AOSD.

【 授权许可】

CC BY